NSN Co. Ltd (031860) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NSN Co. Ltd (031860) has a cash flow conversion efficiency ratio of -0.143x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.89 Billion ≈ $-1.96 Million USD) by net assets (₩20.26 Billion ≈ $13.73 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NSN Co. Ltd (031860) defensive interval to measure how many days the company can operate on defensive assets alone.
NSN Co. Ltd - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how NSN Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
NSN Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NSN Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Harta Djaya Karya Tbk Pt
JK:MEJA
|
0.291x |
|
Embelton Ltd
AU:EMB
|
0.033x |
|
Kingfish Company Nv
OL:KING
|
-0.078x |
|
Park Ha Biological Technology Co., Ltd.
NASDAQ:BYAH
|
N/A |
|
Sahathai Terminal Public Company Limited
BK:PORT
|
0.050x |
|
FASING SA
WAR:FSG
|
0.009x |
|
Nukkleus Inc
NASDAQ:NUKK
|
0.033x |
|
Femasys Inc
NASDAQ:FEMY
|
-0.568x |
Annual Cash Flow Conversion Efficiency for NSN Co. Ltd (2014–2025)
The table below shows the annual cash flow conversion efficiency of NSN Co. Ltd from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see NSN Co. Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩20.26 Billion ≈ $13.73 Million |
₩-8.86 Billion ≈ $-6.01 Million |
-0.437x | -274.65% |
| 2024-12-31 | ₩48.12 Billion ≈ $32.61 Million |
₩-5.62 Billion ≈ $-3.81 Million |
-0.117x | +12.82% |
| 2023-12-31 | ₩59.75 Billion ≈ $40.49 Million |
₩-8.00 Billion ≈ $-5.42 Million |
-0.134x | +29.67% |
| 2022-12-31 | ₩59.58 Billion ≈ $40.38 Million |
₩-11.35 Billion ≈ $-7.69 Million |
-0.190x | +40.54% |
| 2021-12-31 | ₩38.49 Billion ≈ $26.08 Million |
₩-12.33 Billion ≈ $-8.35 Million |
-0.320x | -266.26% |
| 2020-12-31 | ₩51.00 Billion ≈ $34.56 Million |
₩-4.46 Billion ≈ $-3.02 Million |
-0.087x | +54.68% |
| 2019-12-31 | ₩22.70 Billion ≈ $15.38 Million |
₩-4.38 Billion ≈ $-2.97 Million |
-0.193x | +32.29% |
| 2018-12-31 | ₩18.37 Billion ≈ $12.45 Million |
₩-5.23 Billion ≈ $-3.55 Million |
-0.285x | +29.34% |
| 2017-12-31 | ₩20.42 Billion ≈ $13.84 Million |
₩-8.24 Billion ≈ $-5.58 Million |
-0.403x | -46.84% |
| 2016-12-31 | ₩22.41 Billion ≈ $15.18 Million |
₩-6.15 Billion ≈ $-4.17 Million |
-0.275x | +1.90% |
| 2015-12-31 | ₩23.86 Billion ≈ $16.17 Million |
₩-6.68 Billion ≈ $-4.53 Million |
-0.280x | -229.13% |
| 2014-12-31 | ₩29.52 Billion ≈ $20.00 Million |
₩-2.51 Billion ≈ $-1.70 Million |
-0.085x | -- |
About NSN Co. Ltd
DHX Company Co., Ltd. engages in biomedical and distribution businesses in South Korea. The company offers Microbiome to treat intractable skin diseases; REJURUB; and AI digital brain diagnostic device. It also purchases and distributes IT components, including graphics cards, DRAM, CPUs, high-capacity storage, and multi-purpose displays; import and distribution of cosmetics; f and b distribution… Read more